💊 DPP‑4 Inhibitors (Gliptins) for Diabetes: A Complete Guide

When metformin alone isn't enough, doctors often look to add a second medication. One popular class is the DPP‑4 inhibitors, also called gliptins. These oral medications have a favourable profile: they lower blood sugar gently, rarely cause hypoglycemia, and are weight‑neutral. Dr. Ravi Sishir Reddy explains how they work, which ones are available, and what makes them a good choice for many people — especially older adults.

1. What Are DPP‑4 Inhibitors?

DPP‑4 inhibitors are a class of oral medications that work by blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4). This enzyme normally breaks down incretin hormones — GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) — which are released from the gut after a meal. These hormones stimulate the pancreas to release insulin and suppress glucagon, but they are rapidly degraded by DPP‑4, lasting only minutes in the bloodstream. By inhibiting DPP‑4, gliptins prolong the activity of these natural incretins, enhancing the body's own ability to control blood sugar in a glucose‑dependent manner — meaning they work only when blood sugar is elevated, not when it's normal. This is why they have a very low risk of hypoglycemia.

2. Which Drugs Are in This Class?

• Sitagliptin (Januvia): The first and most widely studied DPP‑4 inhibitor. Taken once daily; available in combination pills with metformin.
• Vildagliptin (Galvus): Often taken twice daily. Also combined with metformin.
• Linagliptin (Trajenta): Unique in that it is primarily excreted via bile, not kidneys, so no dose adjustment is needed in kidney disease. Taken once daily.
• Saxagliptin (Onglyza): Taken once daily; dose reduced in kidney impairment.
• Alogliptin (Vipidia): Once daily; dose adjusted for kidney function.
• Teneligliptin: Popular in India and Japan; once daily, well‑tolerated.

All gliptins are available as generics or under brand names. They are often combined with metformin in single‑pill combinations for convenience.

3. Why Are DPP‑4 Inhibitors Prescribed?

• Low risk of hypoglycemia: Because they act only when glucose is high, they rarely cause blood sugar to drop too low, unless combined with sulfonylureas or insulin.
• Weight neutral: Unlike sulfonylureas and insulin, they do not cause weight gain.
• Well tolerated: Generally few side effects; suitable for older adults and those with mild to moderate kidney disease (dose adjustments needed for most except linagliptin).
• Oral administration: No injections required.
• Modest HbA1c reduction: Typically lowers HbA1c by 0.5‑0.8%, making them a good second‑line add‑on after metformin.
• Cardiovascular safety: Large trials have shown they do not increase cardiovascular risk; some agents like sitagliptin have shown neutrality in heart failure.

Dr. Reddy notes that DPP‑4 inhibitors are an excellent option for people who are close to their HbA1c target and need a mild additional reduction, or for those at higher risk of hypoglycemia, such as the elderly.

4. Side Effects and Potential Risks

• Generally well tolerated: Most people experience no side effects.
• Nasopharyngitis and headache: Mild and temporary in a small percentage of users.
• Joint pain (arthralgia): Some patients report joint pain, which can be severe in rare cases. It resolves upon stopping the drug.
• Pancreatitis: A rare but serious side effect reported with all DPP‑4 inhibitors. Symptoms include severe abdominal pain radiating to the back, nausea, and vomiting. If these occur, stop the drug and seek immediate medical attention. However, the absolute risk is very low.
• Skin reactions: Rare cases of bullous pemphigoid (a blistering skin condition) have been reported, particularly with vildagliptin and sitagliptin.
• Heart failure? Saxagliptin and alogliptin have been associated with a slightly increased risk of hospitalisation for heart failure in people with existing heart or kidney disease. This is not a class effect — sitagliptin and linagliptin have not shown this signal. Dr. Reddy advises caution in patients with a history of heart failure, and to discuss the choice of gliptin with your doctor.

5. Who Should Be Cautious or Avoid DPP‑4 Inhibitors?

• Type 1 diabetes: Gliptins are ineffective because beta cells are absent.
• History of pancreatitis: Caution is advised; some guidelines recommend avoiding them.
• Severe kidney impairment: Most DPP‑4 inhibitors require dose reduction; linagliptin is safe without dose adjustment.
• Pregnancy and breastfeeding: Safety has not been established; insulin is preferred.

6. Practical Tips When Taking a Gliptin

• Take once or twice daily as prescribed: They can be taken with or without food. Consistency is key.
• Monitor blood sugar: Especially if you are also on insulin or a sulfonylurea, as the combination can increase the risk of hypoglycemia.
• Be aware of signs of pancreatitis: Severe, persistent abdominal pain should be reported immediately.
• Report any unusual skin blisters or severe joint pain: These are rare but warrant medical evaluation.
• Kidney function tests: Regular monitoring ensures the correct dose, especially for sitagliptin, saxagliptin, and alogliptin.